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Abstract: During the past decades, cancer research has expanded rapidly due to the relatively high incidence 
rate of cancer and high death rate linked to it. The type and the extent of aggressiveness of particular cancers 
are determined by specific flaws in the cell cycle regulation. This study gives a detailed depiction of the cell 
cycle's phases including the checkpoints being the Gl (GAP 1) phase, the Gl/S (Syuthesis) DNA damage 
checkpoint, the S phase, the G2 (GAP2) phase, the G21M (Mitosis) DNA replication checkpoin~ the M phase 
and the interphase. Regulation occurs at all the previous phases mainly through the formation of cyclins-CDKs 
(Cyelin Dependent Kinases) complexes. The latter control precisely the commencement and completion of the 
specific events leading to cell duplication and division by activating various genes such as the Rb 
(Retinoblastoma) gene. CDKs' activity is in turn regulated by various factors such as phosphorylation, 
controlled degradation of cyclins, regulated synthesis of both CDKs and cyclins by growth factors and 
cytokines, as well as by CKIs (Cyclin-dependent kinase inhibitors) such as p15, p16, p18, p19, p2l, p27 and p57. 
The balance between twnour suppressor genes such as p53 and Bax and antiapoptopic genes such as Bcl2 and 
IGF-BP3 has also been demonstrated with a particular focus on p53-"the guardian of the genome". 
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INTRODUCTION 
Cancer is the clonal collection of cells which possess 
high aggressive behaviour (Fearon, 1997) and therefore it 
is considered to be a proliferative disease (Melnick et al., 
1993). Such behaviour is due to genetic instability which 
is defined as an increase in the rate of genomic mutations 
caused by defects in the genes which are responsible for 
the checkpoints in the cell cycle. The latter genes are 
supposed to ensure proper genomic replication (Wodarz 
and Krakauer, 2001). The genomic alteration of the 
mentioned genes gives rise to the activation of 
oncogenes and the inactivation of the twnour suppressor 
genes (Grizzi and Chiriva, 2006). Such mutations cause 
stem cells to become cancerous and are therefore called 
Cancer Stem Cells (CSCs). CSCs retain the properties of 
stem cells and as a result, they are immortal and have 
lllllimited division potential without being subjected to 
aging (Rajaraman, 2006). 
CLASSIFICATION OF CANCERS 
Cancers are usually classified according to their 
behaviour and thus divided into two distinct classes 
being beingn and malignant (Underwood, 2004). However, 
there can be a transition from a benign to malignant state 
leading to metastasis and disease pathology (Wodarz and 
Krakauer, 2001). 
Benign tumours present a slow growth rate with low 
mitotic activity. They are usually non-invasive and do not 
metastasise. In terms of histology, they have a good 
resemblance to normal tissue. They are often 
circwnscribed or encapsulated and are rarely necrotic and 
ulcerative. 
On the contrary, malignant twnours usually present 
high mitotic activity and are always invasive. They are 
usually necrotic and ulcerative and their border is often 
poorly defined. Their nucleus is usually hyperchromatic 
with multiple nucleoli (Underwood, 2004) and they 
metastasise frequently which metastasis occurs via the 
blood stream or lymphatic chains to distant organs 
(Dale et aI., 2004). 
Cancer epidemiology: Lung cancer was the most common 
cancer worldwide in 2002. Approximately 1.4 million 
people are diagnosed with ltmg cancer each year and it 
accollllts for 12% of all cases. Ltmg cancer was also the 
most common cause of death from cancer worldwide in 
2002 andaccollllted to 18% of all deaths from cancer. This 
can be seen in Fig. 1. 
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Fig. 1: The most common causes of death from cancer 
worldwide in 2002 (estimates) (Cancer Research. 
2(07) 
The cell cycle: In order to understand better the 
physiology of cancer, the cell cycle must be studied 
thoroughly. 
The cell cycle, which is depicted in Fig. 2, involves 
mainly four steps which lead to cell growth and cell 
division in order to produce 2 daughter cells. The phases 
are G1, S, G2 and M. 
The G1 stage takes 10-12 h. During this stage, the cell 
synthesises a number of macromolecular constituents 
and builds up mass. It contains 2 copies of each 
clrromosome and therefore it is in a diploid state 
(Underwood, 2004). Late in G1, there is the restriction 
point (R point) which is defined as the point after which 
the cell can complete a division cycle in the absence of 
growth factors. This point divides G1 into intervals being: 
Post-mitotic interval (G1 pm)-this spans 3 to 4 hand 
the cell can "opt" to exit the cell cycle and enter the 
GO phase (Zetterberg et aI., 2001). This phase is 
mitogen dependent (Aguda and Tang, 1999). 
Pre S-phase interval of G1 (G1 ps)-this mitogen 
independent phase (Aguda and Tang, 1999) spans 
from 1-10 h after which the cell can enter the S phase 
(Zetterberg et aI., 2001). 
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Fig. 2: The cell cycle (Darling, 2007) 
During the G1/S checkpoint, DNA damage is sensed 
and the cell cycle is paused until the DNA is thoroughly 
repaired. This ensures that the S phase is embarked only 
when the DNA damage accumulated throughout the 
entire cycle has been eliminated. If the damage is so 
severe, apoptosis can be induced (Barbour et aI., 2006). 
In the S phase, DNA replication occurs and it takes 
6-8 h. The histones and nonhistone proteins are 
deposited on the daughter DNA molecules to reproduce 
the clrromatin structures. This process of doubling the 
genome must occur with extraordinaty precision. If not, 
one of the daughter cells will receive a mutant genome 
that will tlrreaten its ability to survive or causing it to 
become cancerous (UndelWood, 2004). 
The cell enters the G2 phase when genomic 
replication is complete. It now has a DNA content 4 times 
the haploid amolUlt. During G" S, G, phase (Interphase) 
the clrromatin is dispersed tlrroughout the nucleus and is 
actively engaged in transcription to synthesise new 
proteins (UndelWood, 2004). 
The G2iM DNA checkpoint prevents entry into 
mitosis before all DNA is properly replicated and no 
replication foms are left (Barbour et aI., 2006). 
:Mitosis (nuclear division) together with cytokinesis 
(cytoplasmic division) make up this phase of the cell 
cycle. It is further divided into phases. 
Prophase: The centrosomes elaborate microtubules which 
attach to the cell periphery as well as to tubules from the 
opposite centrosome. Centrosomes start moving to the 
opposite poles of the cell. The chromosomes condense 
and can be seen as a pair of sister clrromatids. 
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Prometaphase: The nuclear envelope disintegrates and 
mitotic spindle tubules attach themselves to the 
chromosomes' kinetochores. 
Metaphase: A pause occurs whilst all kinetechores attach 
bipolarly to the spindle microtubules. The mitotic spindle 
attachment checkpoint prevents entry into Anaphase 
before all chromosome centromeres are bipolarly attached 
to the mitotic spindle. 
Anaphase: Cohesins are degraded by proteolysis which 
results in the separation of the chromosomes by the 
mitotic spindle. 
Telophase: The nuclear membrane fe-assembles arOlllld 
chromosomes at the poles (Underwood. 2004). 
CELL CYCLE REGULATION 
The Cdk's (cyelin-dependant protein kinases) drive 
the events that occur during the cell cycle and can be 
described as the clock that times it all. In more complex 
cell cycles Cdk's also process information by integrating 
the extracellular and intracellular signals involved to allow 
the cell cycle to proceed despite any environmental 
change or mechanical failure. 
The catalytic subunits of the Cdk depend 
primarily on the associated cyclin subllllits (whose 
alternating concentrations cause the stage-specific 
timing of the Cdk) and then on protein kinases, regulatory 
sub mil.ts, substrate recognition and sub-cellular location. 
All these ensure the precise time of onset and co-
ordination of the mechanical events OCCWTing in the cell 
that cause cell duplication and cell division (Morgan, 
1997). 
Table 1 illustrates the various Cdk's involved in the 
entire cell cycle together with their associated cyclin and 
in which phase do they participate. 
Table 1: Major Cdk's, their associated cyclins and the cycle phase in which 
they participate (Morgan, 1997) 
Cdk 
Cdk 1 (Cdc2) 
Cdk2 
Cdk3 
Cyclin partner 
CyclinB 
CyclinE 
CyclinA 
Role 
M phase 
GlIS phase 
S phase and G2 
Cdk4 CyclinD Gl 
Cdk 5 p35 Neural differentiation 
Cdk 6 Cyclin D G 1 
Cdk 7 Cyclin H CAKItranscription 
Cdk 8 Cyclin C Transcription 
*Cdk3 is closely related to Cdc2 and Cdk2. This Cdk carmot be easily 
detected in a mammalian cell. Its associated cyclin has not yet been 
identified 
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There are various mechanisms to regulate the CDK 
activity so as to control the metabolic activities inside the 
cell: 
• 
• 
• 
• 
Phosphorylation. 
Controlled degradation of cyclin. 
Regulated synthesis of CDK and cychn by growth 
factors and cytokines. 
Inhibition of CDK (Underwood. 2004). 
REGULATION AT TIlE GO-GI-S PHASE 
Cdk4 and Cdk6 are very closely related due to their 
common cyclin partner (Cyclin D). Their activation gives 
a response to growth factors in certain cell types (they 
couple this with extracellular sigmls) (Morgan, 1997). The 
cyclin D-CDK4/6 assembly occurs first in mid-Gl and 
increases to a maximwn near the G I-S transition and 
persist as long as mitogenic stimulation continues. 
p16. pIS. pIS and p19 are 4 INK4 proteins which act 
as CKIs (cyclin-dependent kimse Inhibitors) for CDK4 
and CDK6 causing a G 1 phase arrest. This demonstrates 
the fact that CDK4/6-cyclin D interaction is vital for 
passage through the restriction point and exit of G 1 phase 
(Sherr. 1996). This occurs via the Retimblastoma (Rb) 
Pathway. Retinoblastoma gene is a twnour suppressor 
gene. Its product (Rb protein) and other Rb-like proteins 
such as p130 and pl07 bind to E2F complexes when they 
are in their hypophosphorylated form and repress the E2F 
complexes from activating target genes required for the 
onset of the S-phase. 
The CDK4/6-cychn D complex triggers the 
phosporylation of the Rb and Rb-hke proteins and 
therefore frees the E2F complexes which can then 
transactivate other genes (Sherr, 1996) required for DNA 
synthesis and of certain cyclins such as Cyclin E and 
cychn A (Morgan. 1997). This phosphorylation is later 
hastened by the cyclin E-CDK2 complex showing that a 
positive feedback exists to enhance the rate at which Rb 
phosphorylation, E2F release, gene transactivation and 
entry to the S-phase occur (Sherr. 1996). 
Rb is maintained in its hyperphosphorylated fonn by 
cyclin A and cyclin B-dependent kinases throughout the 
rest of the cell cycle after completion of mitosis and re-
entry to the G 1 or GO phase (Sherr. 1996). 
Once the S-phase is triggered, degradation of E2F 
and cyclin E is initiated with the latter being targeted for 
destruction by phosphorylation by CDK2 and then is 
degraded by proteolysis after ubiquination. 
At this stage, a rise in cyclin A-CDK2 is also 
observed which prevent the interaction between DNA 
and E2Fs thus preventing further gene trans activation. 
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CycliTIs D-. E- and A-dependent kinases are inhibited 
by the CKls p21. p27 and p57. p27 is important in the 
control of the restriction point and its levels are high in 
cells which have exited the cell cycle (quiescent cells) 
since it inhibits cyclin E-CDK2 and cyclin A-CDK2 
activity. The latter occurs as a result of a rise in cyelin D-
CDK complexes. Translational and post-translational 
mechanisms control the level of p27 and its rate of 
twnover is increased by cyelin E-CDK2 mediated 
phosphorylation (Sherr. 1996). 
In cancer cells, gene amplification and translocation 
at the Dl locus on chromosome 11 q13 was observed 
which causes the overexpression of eyelin Dl. The same 
happens in the case of CDK4. This was demonstrated in 
squamous cell carcinomas of the head and neck, 
esophageal carcinomas, bladder cancer, primary breast 
carcinoma, small-cell hmg twnors and hepatocellular 
carcinomas. In melanoma, biliary tract and esophageal 
carcinomas, mutations that disable the CDK inhibitory 
fllllction of the INK4a gene on chromosome 9p21 was 
noted. A mutation in the CDK4 which prevented 
interaction with p16 was fOlllld in melanoma. 
Homozygous deletions of the INK4a locus have also been 
discovered and accollllted for gliomas, mesotheliomas, 
nasopharyngeal carcmomas, acute lymphocytic 
leukaemias, sarcomas, bladder and ovarian twnours. Rb 
loss has been linked to carcinogenesis. This has been 
tested on transgenic mice being Rb -/- heterozygotes 
which developed midlobe Rb-deficient pituitary hwnours. 
In hwnans, retinoblastomas, osteosarcomas, carcinoid 
twnours and small cell hmg cancers were blamed on Rb 
inactivation. This also proves the fact that not all cell 
types are sensitive to Rb loss (Sherr, 1996). Mutations in 
pl07 or p130 have not been fOlllld in cancer cells. 
Regarding to the connection of E2F with cancers, the 
elimination of both wild-types E2Fl allelles in mice leads 
to developmental defects in some tissues and to tumors 
in others. Hwnans exhibit different results since 
alterations in a single E2F complex might be adequately 
compensated. Alterations in the cyclin E and cyclin A 
genes in hwnan cancers also appear to be very rare. 
Overexpression of cyclin E is observed in carcinomas of 
the breast, stomach, colon and endometriwn (Sherr, 1996). 
The G 1 checkpoint is predominantly dependent on p53 
which is a twnor suppressor gene. The p53 gene is 
considered as the most studied tumor suppressor gene 
(Seemann et al., 2004). It accwnulates when the cell is 
exposed to ultraviolet light, gamma-irradiation and to a 
range of chemotherapeutic drugs all of which cause 
genotoxic stress (Lane, 1992). It regulates a nwnber of 
genes which are involved in cell-cycle arrest at Gland 
DNA repair after detecting DNA damage before genomic 
replication occurs (Seemann et aI., 2004). If the latter fails, 
p53 may trigger cell death by apoptosis (Lane. 1992). As 
254 
a result, p53 is nicknamed "the guardian of the genome" 
since it prevents the propagation of defective genome to 
subsequent daughter cells (Speidel e/ 01 .• 2006). 
p53: The human p53 gene has been mapped on the p arm 
of chromosome 17 at the 13.1 locus (l7pI3.1). It is 
composed of 20 kb with 11 exons, with the first one being 
non-coding. It has got a nwnber of potential sites for 
transcriptional regulation such as those for Spl, NF-
kappaB or C-Jllll. Still, most of the protein regulation 
occurs at the post-translational level. It encodes for a 
53kDa phosphoprotein composed of 393 amino acids. It 
binds DNA sequences corresponding to repeats of 
RRRC(A/T)-(T/A)GYYY (R is a purine. Y is a pyrimidine). 
The protein has got five structural domains: 
• N -terminal transactivation domain. 
• Proline-rich regulatory domain. 
• Sequence specific DNA binding domain. 
• Oligomerisation domain (Seemann et al., 2004). 
• C-terminal domain involved in DNA binding which 
can be upregulated by phosphorylation (Mowat. 
1998). 
The DNA binding domain consists of beta-sheets 
that supports flexible loops and helixes that are in direct 
contact with DNA. A zinc atom interacts with the 
mentioned loops and helixes and stabilises them. In 
cancer, mutations of this structure are observed which 
include the inhibition of protein-DNA contacts and the 
disruption of protein folding (Seemann e/ 01.. 2004). 
The p53 gene is a facultative gene since it is almost 
dormant in most cells and it is susceptible to degradation 
by proteasomes after ubiquination. Mdm2 is a ring-finger 
protein which interacts with a short domain in the N-
terminus of p53. It affects the p53 in three ways: 
• It exports it out of the nucleus (which is its location 
of action) into the cytoplasm 
• Inhibits the activation of p53-dependent gene by 
preventing it from binding to transcriptional 
machinery therefore masking its expression. This 
occurs since the Mdm2 gene binds to the 
transcriptional activation domain of p53. 
• Induces the binding of ubiquitin chains to lysines 
located on the C-terminus of p53 making it 
susceptible to degradation by proteasomes 
An auto-regulatory mechanism is observed in the 
interaction between p53 and Mdm2 where the latter gene 
is activated by the p53 itself. When the p53 protein rises, 
an increased activation of the Mdm2 gene is observed 
which in turn deactivates the p53 protein and therefore 
reducing its levels to normal values. 
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Overexpression of the Mdm2 gene increases the 
degradation of p53 and therefore increasing the cell's 
susceptibility to cancer (Seem31lll et aI., 2004). 17 out of 
47 hlllllan sarcomas show this behaviour (Lane, 1992). 
Stabilisation of the p53: The p53 protein can be stabilised 
through various pathways in response to DNA damage 
being phosphorylation by stress-signalling or growth 
signalling kinases such as Casein Kinase 1 (CKl), Casein 
Kinase 2 (CK2). Checkpoint Kinase 2 (Chk2). Ataxia 
Telangiectasia Mutated kinase (AIM), Ataxia 
Telangiectasia mutated Related kinase (AIR), Protein 
Kimse C (PRKC). c-Jun N-terminal kimse (INK) and 
Mitogen-Activated Protein Kinase J\1APK and acetylation 
by co-activator histone acetyl transferases such as p300. 
The main pathway involves the sensing of DNA damage 
by the AIM kimse and phosphorylation of p53 at the 
Mdrn2 binding site and the disruption of p53-Mdrn2 
interaction and therefore leading to p53 nuclear 
acclllllulation (Seemann et aI., 2004). 
Another important pathway for the control of p53 
involves p14 which expression is activated in response to 
growth stimuli and controlled by the E2Fl transcription 
factor. p14 binds to Mdm2 and restrain its location within 
the nucleolus and as a result, free p53 can be released in 
the nucleus (Seemann. 2004). A deletion of the pl4 gene 
results in the removal of inhibition on Mdm2 and therefore 
p53 degradation is kept llllder control. Tlllllours in the 
brain, breast and lllllgs might exhibit such behaviour 
(Vogelstein. 2000). 
p53 activity: Once stabilised, p53 can trigger both 
transcription dependent and transcription independent 
pathways. Transcription independent pathways include 
the binding to components of DNA replication/repair 
machinery such as the helicases ERCC2 and ERCC3 while 
transcription dependent pathways include the genetic 
activation of: 
o Cell cycle regulators in the Gland G2 phases-ego p21. 
o Regulators of apoptosis-eg. BAX. FAS. Bcl-2. IGF-
BP3. 
• Genes involved in cellular response to stress-ego 
NOS2 and COX2. 
• Genes involved in DNA repair (06-methylguanine 
methyllransferase (O,MGMI) and MSH2) (Seemann 
e/ 01 .• 2004). 
Mutations of p53 linked to cancers: Mutations of p53 
have been observed in all types of cancers but they vary 
with different cell types. In for example cancers of the 
aero-digestive tract, TP53 is mutant in up to 75% of the 
cases of invasive cancers (Seemann et aI., 2004). 
Seventy five percent of TP53 mutations are missense 
of which 80% are located within the sequence encoding 
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the DNA-binding domain of the protein. There is only a 
2% chance of a mutation in the C-terminal and N -terminal 
(Seemann e/ 01.. 2004). A deletion of the carboxy-terminal 
domain prevents the formation of p53 tetramers and is 
fOlllld in occasional cancers at many different sites 
(Vogelstein. 2000). 
At least two mutated residues in the trans activation 
domain (Amino-terminal) are required to disrupt the p53 
transcriptional activity. 
In the DNA-binding domain, mutations have been 
observed in the majority of the residues although some 
are more frequent than others. These disrupt the protein-
DNA interactions. Such an example is the amino acid 
changing mutation in this domain which will prevent p53 
from binding to defective DNA sequences and is 
observed in colon, breast, lllllg, bladder, brain pancreas, 
stomach and oesophageal cancers amongst others 
(Seemann e/ 01 .• 2004). 
Its important to note that not all p53 mutations pave 
the way for cancers. Such mutations are called "silent 
mutations" and accollllt for 4.4% of all mutations 
(Seemann e/ 01 .• 2004). 
ERCC2 and ERCC3: ERCC2 and ERCC3 form part of a 
TFIIH complex having both kinase and helicase activity. 
The TFIIH complex plays an important role in 
transcription and in DNA excision repair. p53 in its 
wild-type and mutant form inhibits both the ERCC2 and 
ERCC3 in vitro, thus initiating apoptosis. Fibroblasts with 
mutated ERCC2 and ERCC3 experienced reduced level of 
binding and therefore inhibition by p53 resulting in 
reduced apoptosis. 
p21WAFl/CIPl: The p21 WAFlICIPl, which is considered to be a 
Cyclin dependent Kinase Inhibitor (CKI). is activated by 
p53 and inhibits effectively the Gl/S cyclin dependent 
kinases Cdk2. Cdk3. Cdk4. Cdk6 kinases and inhibits 
weakly the G2 active cdc2 kimse (CDK1) (Mowa~ 1998). 
p21 WAFlICIPl can also be activated via p53 independent 
pathways by inducing interaction of transcription factors 
with the p21 promoter. This induction occurs by various 
agents such as phorbol ester (P1.1A), okadoic acid, the 
tlllllOur suppressor protein BRCAl, transforming growth 
factor-~ (IGF-~). calcium. butyrate. lovastatin. histone 
deacetylase inhibitor Irichostatin A (ISA) and Nerve 
Growth Factor (NGF) (Blundell. 2006). 
p21 WAFlICIPl is also involved in the transcription 
control of the PIG3 gene which is involved in the ROS 
pathway. Once activated, the PIG3 gene induces reactive 
oxygen species which are released from the mitochondria 
resulting in cell apoptosis (Macip e/ 01 .• 2002). 
If proliferation is considered, p21 WAFlICIPl was fOlllld 
to either promote or inhibit this process depending on the 
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specific cellular context. An increase in tumorogenesis 
was observed in p21 WAFl!CIPI knockout mice (Bhmdell, 
2006) due to the interruption of the G liS checkpoint. 
Bel2 and Bax: The Bel2 gene is considered to be an 
antiapoptopic gene. The Bel2 protein inhibits apoptosis 
and this was demonstrated in the differentiation of 
myeloid cells into granulocytes where its levels decrease 
and they lllldeIWent apoptosis (N mnnovski et aI., 1996). 
In contrast, the Bax gene, which is a member of the 
Bcl-2 gene family is considered to be an apoptopic gene. 
It is activated by p53 since p53 DNA-binding sequences 
have been fOlllld ill the Bax gene promoter. 
Overexpression of p53 gives rise to increase in Bax gene 
expression and direct increase in Bcl-2 gene repression 
(Mowat. 1998). The Bax protein mcreases the 
mitochondrial membrane permeability and stimulates cyt 
c release into the cytoplasm which activates the caspases 
enzymes (Jfugensmeier. 1998). 
Caspases are a class of proteases which degrade 
essential cellular proteins and thus inititate apoptosis. 
They can also couple with death receptors in the 
membrane such as Fas and TNFR (Tlllllor Necrosis 
Factor). The Fas receptor is upregulated by the p53. The 
docking of the Fas ligand to the Fas receptor was fOlllld 
to induce apoptosis III activated T -lymphocytes. 
Dowmegulation of Fas receptor as a result of loss of p53 
will interrupt cell death in tumors (Mowat. 1998). 
IGF-BP3 (Insulin Growth Factor I-Binding Protein 3): 
Insulin Growth Factor I (IGF-I) binds to the IGF-I 
receptor to stimulate smvival, differentiation and 
proliferation (Misawa et aI., 2000). It can suppress 
apoptosis induced by the overexpression of the Myc 
oncogene. The p53 upregulates the expression ofIGF -BP3 
which will bind to IGF -I and prevent it from docking to its 
receptor. p53 also directly represses the activity of the 
IGF-l receptor gene. Therefore, the cell's susceptibility to 
apoptosis is increased. Mutations in p53 causing its 
disability will result in the increase ofIGF-l receptors 
and the tumor cell will be protected from apoptosis 
(Mowat. 1998). 
Regulation at the interphase: At interphase, Cdk7 is one 
of the major Cdk-Activating Kinases (CAK). These 
phosphorylate the Cdk subllllit for complete activation. 
The Cdk7 -cyclin H complex is associated with the 
transcription factor TFIlli. Thus here it can act as a kinase 
that phophorylates the RNA polymerase II C-terrninal 
domain during the process of transcription. This shows 
the involvement of Cdk7 in transcription and the cell 
cycle. 
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Regulation at the G2!M phase: For instance, Cyclin Band 
Cyclin A bind to p34cdc, (also known as CDK-I) and 
induce the activation of p34cdc2 by triggering the critical 
dephosphorylation of the kinase especially Thr-14 and 
Tyr-15. The active p34CdC2_cyclin B complex fllllctions as 
the Mitosis Promoting Factor (1.1PF) as it initiates mitosis. 
p53 is also involved in the control of the G2!M phase. 
It has been demonstrated that the cell cycle was blocked 
at the G2!M phase as a result of the overexpression of the 
Mos oncogene and members of the 1.1AP kinase pathway 
(including activated Ras. Raf and MEK oncogenes) which 
pathway is dependent on p53. Centrosome duplication 
also falls under the control of p53. This has been 
demonstrated in p53 deficient cells where multiple 
copies of centrosomes and changes in the spindle 
checkpoint control have been observed. This resulted 
in the disruption of normal chromosomal separation 
(Mowat. 1998). 
Expression of telomerase: The expression of telomerase 
may also lead to carcinogenesis. Telomeres are non-
coding repetitive sequences fOlllld at the ends of 
chromosomes (Weinstein and Ciszek, 2002). In hlllllans 
they consist of TTAGGG repeats to form linear tandem 
arrays (Zhong e/ al .• 2007). These sequences have a 
protective role as they prevent the chromosomes from 
fusing into rings and also prevent them from binding to 
other DNA sequences, thus maintaining their stability and 
integrity (Weinstein e/ al .• 2002; Zhong e/ al .• 2007). This 
explains why any telomere loss leads to somatic cell line 
mortality. Telomeres shorten with every cell division by 50 
to 150 base pairs (Zhong e/ al .• 2007) as the enzyme 
molecules are llllable to reproduce completely the 
chromosomal ends (Weinstein et aI., 2002). This does not 
affect cellular fllllction lllltil a point has been reached 
where at least one of the telomere sequences has become 
critically short (Weinstein e/ al .• 2002). This leads to the 
disabling of the replicative mechanisms (Weinstein et al., 
2002) and withdrawal from the cell cycle (Zhong e/ al .• 
2007) and therefore cell aging. 
T elomerase IS a reverse transcriptase which 
elongates telomere sequences, by using its RNA template 
to add Guanine rich repeats to the 3' end, (Gilinus-Akay 
e/ al.. 2007; Weinstein e/ al .• 2002) while acting together 
with telomere-binding proteins (Weinstein et aI., 2002). 
Studies have shown the link between telomeres, 
telomerase and cancer since the telomerase is therefore 
inactivating the aging process and leading to cell 
immortality or twnorigenesis (Weinstein et aI., 2002). This 
is shown by the fact that most cancer cells are capable of 
preventing telomere shortening by means of the 
activation of either telomerase, a telomere maintenance 
mechanism, or alternative lengthening of telomeres. The 
enzyme telomerase is strongly suppressed in hlllllan 
View publication stats
Res. J. BioI. Sci .• 3 (2): 251-257.2008 
somatic cells but its activity is resllllled in highly 
proliferative tissues as well as in cancer cells (Zhong 
e/ 01 .• 2007). 
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